A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
NCT ID: NCT03725202
Last Updated: 2025-03-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
438 participants
INTERVENTIONAL
2019-02-06
2025-02-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Safety and efficacy data through 06 February 2024 are included in the interim analysis, which was conducted after all participants completed the Week 52 visit or discontinued from the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
NCT04161898
A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)
NCT03192969
Ustekinumab for the Treatment of Giant Cell Arteritis
NCT02955147
Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis
NCT03711448
Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering
NCT04012905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo + 52-week CS taper
Participants received placebo tablets for upadacitinib administered orally once daily (QD) for 52 weeks and a 52-week corticosteroid (CS) taper regimen during Period 1.
Corticosteroid (CS)
At Baseline, all participants switched to corticosteroids (CS) provided by the sponsor with the oral prednisone or prednisolone dose at 20, 30, 40, 50, or 60 mg QD. The initial dose of prednisone or prednisolone was at the discretion of the investigator, based on disease severity and comorbid medical conditions, at a minimum of 20 mg QD at Baseline. At Baseline, if a participant was on a dose other than 20, 30, 40, 50, or 60 mg QD, the dose was rounded up or down, as clinically indicated per investigator discretion, to the nearest of these doses. Prednisone or prednisolone was tapered according to a predefined schedule over a 26- or 52-week period. Open-label prednisone or prednisolone was provided until the dose was tapered to 20 mg/day. Subsequently, blinded prednisone or prednisolone was provided for the remaining blinded taper regimen through Week 52.
Placebo
Administered orally once a day
7.5 mg Upadacitinib + 26-week CS taper
Participants received 7.5 mg upadacitinib tablets administered orally once daily (QD) for 52 weeks and a 26-week corticosteroid (CS) taper regimen during Period 1.
Upadacitinib
Administered orally once a day
Corticosteroid (CS)
At Baseline, all participants switched to corticosteroids (CS) provided by the sponsor with the oral prednisone or prednisolone dose at 20, 30, 40, 50, or 60 mg QD. The initial dose of prednisone or prednisolone was at the discretion of the investigator, based on disease severity and comorbid medical conditions, at a minimum of 20 mg QD at Baseline. At Baseline, if a participant was on a dose other than 20, 30, 40, 50, or 60 mg QD, the dose was rounded up or down, as clinically indicated per investigator discretion, to the nearest of these doses. Prednisone or prednisolone was tapered according to a predefined schedule over a 26- or 52-week period. Open-label prednisone or prednisolone was provided until the dose was tapered to 20 mg/day. Subsequently, blinded prednisone or prednisolone was provided for the remaining blinded taper regimen through Week 52.
15 mg Upadacitinib + 26-week CS taper
Participants received 15 mg upadacitinib tablets administered orally once daily (QD) for 52 weeks and a 26-week corticosteroid (CS) taper regimen during Period 1.
Upadacitinib
Administered orally once a day
Corticosteroid (CS)
At Baseline, all participants switched to corticosteroids (CS) provided by the sponsor with the oral prednisone or prednisolone dose at 20, 30, 40, 50, or 60 mg QD. The initial dose of prednisone or prednisolone was at the discretion of the investigator, based on disease severity and comorbid medical conditions, at a minimum of 20 mg QD at Baseline. At Baseline, if a participant was on a dose other than 20, 30, 40, 50, or 60 mg QD, the dose was rounded up or down, as clinically indicated per investigator discretion, to the nearest of these doses. Prednisone or prednisolone was tapered according to a predefined schedule over a 26- or 52-week period. Open-label prednisone or prednisolone was provided until the dose was tapered to 20 mg/day. Subsequently, blinded prednisone or prednisolone was provided for the remaining blinded taper regimen through Week 52.
Placebo + 52-week CS taper -> Placebo
Participants who achieved sustained remission for at least 24 weeks prior to the Week 52 visit (at the end of Period 1) OR at remission at the Week 52 visit only who were assigned to placebo tablets for upadacitinib administered orally once daily (QD) in Period 1 continued to receive placebo tablets for upadacitinib administered orally once daily (QD) in Period 2.
Placebo
Administered orally once a day
7.5 mg Upadacitinib + 26-week CS taper -> 7.5 mg Upadacitinib
Participants received 7.5 mg upadacitinib tablets administered orally once daily (QD) in Period 2.
Upadacitinib
Administered orally once a day
7.5 mg Upadacitinib + 26-week CS taper -> Placebo
Participants received placebo tablets for upadacitinib administered orally once daily (QD) in Period 2.
Placebo
Administered orally once a day
15 mg Upadacitinib + 26-week CS taper -> 15 mg Upadacitinib
Participants received 15 mg upadacitinib tablets administered orally once daily (QD) in Period 2.
Upadacitinib
Administered orally once a day
15 mg Upadacitinib + 26-week CS taper -> Placebo
Participants received placebo tablets for upadacitinib administered orally once daily (QD) in Period 2.
Placebo
Administered orally once a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Upadacitinib
Administered orally once a day
Corticosteroid (CS)
At Baseline, all participants switched to corticosteroids (CS) provided by the sponsor with the oral prednisone or prednisolone dose at 20, 30, 40, 50, or 60 mg QD. The initial dose of prednisone or prednisolone was at the discretion of the investigator, based on disease severity and comorbid medical conditions, at a minimum of 20 mg QD at Baseline. At Baseline, if a participant was on a dose other than 20, 30, 40, 50, or 60 mg QD, the dose was rounded up or down, as clinically indicated per investigator discretion, to the nearest of these doses. Prednisone or prednisolone was tapered according to a predefined schedule over a 26- or 52-week period. Open-label prednisone or prednisolone was provided until the dose was tapered to 20 mg/day. Subsequently, blinded prednisone or prednisolone was provided for the remaining blinded taper regimen through Week 52.
Placebo
Administered orally once a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of erythrocyte sedimentation rate (ESR) \>= 50 mm/hour or high sensitivity C-reactive protein (hsCRP)/CRP \>=1.0 mg/dL
* Presence of at least one of the following: Unequivocal cranial symptoms of GCA or Unequivocal symptoms of polymyalgia rheumatica (PMR)
* Presence of at least one of the following: temporal artery biopsy revealing features of GCA or evidence of large vessel vasculitis by angiography or cross-sectional imaging such as ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) or positron emission tomography (PET).
* Active GCA, either new onset or relapsing, within 8 weeks of Baseline.
* Participants must have received treatment with \>=40 mg prednisone (or equivalent) at any time prior to Baseline and be receiving prednisone (or equivalent) \>= 20 mg once daily (QD) at Baseline.
* Participants must have GCA that, in the opinion of the investigator, is clinically stable to allow the participant to safely initiate the protocol-defined corticosteroid (CS) taper regimen.
* Females must either be postmenopausal or permanently surgically sterile or, practicing at least 1 specified method of birth control through the study.
Exclusion Criteria
* Treatment with an interleukin-6 (IL-6) inhibitor within 4 weeks of study start, or prior treatment with an IL-6 inhibitor and experienced a disease flare during treatment.
* Use of any of the following systemic immunosuppressant treatments within the specified timeframe prior to study start:
* Anakinra within 1 week of study start.
* Methotrexate, hydroxychloroquine, cyclosporine, azathioprine, or mycophenolate within 4 weeks of study start.
* Oral corticosteroid (CS) for conditions other than GCA within 4 week of study start, or intravenous CS within 4 weeks of study start.
* Greater than or equal to 8 weeks for leflunomide if no elimination procedure was followed, or adhere to an elimination procedure.
* Cell-depleting agents or alkylating agents including cyclophosphamide within 6 months of study start.
* Current or past history of infection including herpes zoster or herpes simplex, human immunodeficiency virus (HIV), active Tuberculosis, active or chronic recurring infection, active hepatitis B or C.
* Female who is pregnant, breastfeeding, or considering pregnancy during the study.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rheum Assoc of North Alabama /ID# 168668
Huntsville, Alabama, United States
Arizona Arthritis and Rheumatology Research - Glendale Office /ID# 204702
Glendale, Arizona, United States
VA Long Beach Healthcare System /ID# 203833
Long Beach, California, United States
Robin K. Dore MD, Inc /ID# 201950
Tustin, California, United States
Denver Arthritis Clinic /ID# 171552
Denver, Colorado, United States
Duplicate_Western Connecticut Health Network- Germantown Rd /ID# 205071
Danbury, Connecticut, United States
Rheumatology Associates of South Florida (RASF) - Clinical Research /ID# 169040
Boca Raton, Florida, United States
Lakes Research, LLC /ID# 210442
Miami, Florida, United States
Ctr Arthritis & Rheumatic Dise /ID# 168667
Miami, Florida, United States
Medallion Clinical Research Institute, LLC /ID# 168666
Naples, Florida, United States
Omega Research Group /ID# 201903
Orlando, Florida, United States
IRIS Research and Development, LLC /ID# 169406
Plantation, Florida, United States
Clinical Research of West Florida - Tampa /ID# 201899
Tampa, Florida, United States
Clinical Research of West Florida, Inc /ID# 201901
Tampa, Florida, United States
Duplicate_University of South Florida /ID# 207077
Tampa, Florida, United States
Lovelace Scientific Resources /ID# 169041
Venice, Florida, United States
Arthritis and Rheumatology /ID# 170295
Atlanta, Georgia, United States
Institute of Arthritis Research /ID# 168490
Idaho Falls, Idaho, United States
Duplicate_Rush University Medical Center /ID# 224581
Chicago, Illinois, United States
Ochsner Clinic Foundation /ID# 200723
Baton Rouge, Louisiana, United States
The Arthritis & Diabetes Clinic, Inc. /ID# 171199
Monroe, Louisiana, United States
Ochsner Clinic Foundation-New Orleans /ID# 171200
New Orleans, Louisiana, United States
Louisiana State Univ HSC /ID# 202646
Shreveport, Louisiana, United States
Rheumatology Associates PA - Portland /ID# 225011
Portland, Maine, United States
The Center for Rheumatology and Bone Research /ID# 168652
Wheaton, Maryland, United States
University of Michigan Hospitals /ID# 168645
Ann Arbor, Michigan, United States
Wayne State University Health Center /ID# 212755
Detroit, Michigan, United States
Henry Ford Medical Center - New Center One /ID# 207456
Detroit, Michigan, United States
Duplicate_AA Medical Research Center - Grand Blanc /ID# 201854
Grand Blanc, Michigan, United States
Duplicate_West Michigan Rheumatology /ID# 168647
Grand Rapids, Michigan, United States
Clinvest Research LLC /ID# 208182
Springfield, Missouri, United States
Physician Research Collaboration, LLC /ID# 168610
Lincoln, Nebraska, United States
University Clinical Research Center /ID# 202504
Somerset, New Jersey, United States
University of Rochester Medical Center /ID# 213527
Rochester, New York, United States
Marietta Memorial Hospital /ID# 210834
Marietta, Ohio, United States
STAT Research, Inc. /ID# 200436
Vandalia, Ohio, United States
University of Pennsylvania /ID# 168655
Philadelphia, Pennsylvania, United States
Piedmont Arthritis Clinic, PA /ID# 212431
Greenville, South Carolina, United States
Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 212761
Summerville, South Carolina, United States
West Tennessee Research Institute /ID# 209256
Jackson, Tennessee, United States
Arthritis Associates of Kingsport /ID# 212756
Kingsport, Tennessee, United States
Allen Arthritis /ID# 225527
Allen, Texas, United States
Tekton Research, L.L.C /ID# 201801
Austin, Texas, United States
Precision Comprehensive Clinical Research Solutions /ID# 201798
Colleyville, Texas, United States
West Texas Clinical Research /ID# 204834
Lubbock, Texas, United States
Arthritis and Rheumatology Institute, PLLC /ID# 214612
Plano, Texas, United States
Baylor Scott & White Center for Diagnostic Medicine /ID# 213529
Temple, Texas, United States
University of Vermont Medical Center /ID# 211179
Burlington, Vermont, United States
Carilion Clinic /ID# 212928
Roanoke, Virginia, United States
Kadlec Clinic Rheumatology /ID# 201618
Kennewick, Washington, United States
University of Washington /ID# 201619
Seattle, Washington, United States
Aurora Rheumatology and Immunotherapy Center /ID# 201853
Franklin, Wisconsin, United States
Froedtert Memorial Lutheran Hospital /ID# 224557
Milwaukee, Wisconsin, United States
Emeritus Research Sydney /ID# 201937
Botany, New South Wales, Australia
Prince of Wales Hospital /ID# 210995
Randwick, New South Wales, Australia
Griffith University /ID# 223829
Southport, Queensland, Australia
The Queen Elizabeth Hospital /ID# 201939
Woodville South, South Australia, Australia
Emeritus Research /ID# 201938
Camberwell, Victoria, Australia
Fiona Stanley Hospital /ID# 201941
Murdoch, Western Australia, Australia
Medizinische Universitaet Innsbruck /ID# 201786
Innsbruck, Tyrol, Austria
Rheuma-Zentrum Wien-Oberlaa GmbH /ID# 201781
Vienna, Vienna, Austria
Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 224334
Yvoir, Namur, Belgium
UZ Gent /ID# 202778
Ghent, Oost-Vlaanderen, Belgium
Universitair Ziekenhuis Leuven /ID# 202779
Leuven, Vlaams-Brabant, Belgium
Duplicate_University of Alberta Hospital - Division of Hematology /ID# 208629
Edmonton, Alberta, Canada
St. Joseph's Healthcare /ID# 204160
Hamilton, Ontario, Canada
CISSSBSL -Hopital regional de Rimouski /ID# 224266
Rimouski, Quebec, Canada
Centre de Recherche Musculo-Squelettique /ID# 201224
Trois-Rivières, Quebec, Canada
Rheumatology Associates /ID# 201843
Saskatoon, Saskatchewan, Canada
Fakultni nemocnice Olomouc /ID# 202041
Olomouc, , Czechia
Axon Clinical, s.r.o. /ID# 202468
Prague, , Czechia
Medical Plus, s.r.o. /ID# 200865
Uherské Hradiště, , Czechia
Aarhus University Hospital /ID# 171177
Aarhus C, Central Jutland, Denmark
Sydvestjysk Sygehus /ID# 200216
Esbjerg, Region Syddanmark, Denmark
Hopital Saint Joseph /ID# 171540
Marseille, Bouches-du-Rhone, France
CHU Dijon /ID# 225277
Dijon, Cote-d Or, France
Hopital de la Cavale Blanche /ID# 171549
Brest, Finistere, France
CHU Toulouse - Hopital Purpan /ID# 171547
Toulouse, Haute-Garonne, France
CHRU Lille - Hopital Claude Huriez /ID# 171543
Lille, Nord, France
Hopitaux Universitaires Paris Centre-Hopital Cochin /ID# 171545
Paris, Paris, France
CHU de Nantes, Hotel Dieu -HME /ID# 171544
Nantes, Pays de la Loire Region, France
HCL - Hopital de la Croix-Rousse /ID# 211184
Lyon, Rhone, France
CHU de CAEN - Hopital de la Cote de Nacre /ID# 171539
Caen, , France
CHRU Tours - Hopital Trousseau /ID# 245232
Chambray-lès-Tours, , France
Hopital Pitie Salpetriere /ID# 171542
Paris, Île-de-France Region, France
Medius Klinik Kirchheim /ID# 200637
Kirchheim unter Teck, Baden-Wurttemberg, Germany
Universitaetsklinikum Tuebingen /ID# 223854
Tübingen, Baden-Wurttemberg, Germany
Universitaetsklinikum Wuerzburg /ID# 213340
Würzburg, Bavaria, Germany
Immanuel Krankenhaus Berlin /ID# 223855
Buch, , Germany
Medizinische Versorgungszentren Burghausen Altoetting /ID# 208773
Burghausen, , Germany
Medizinische Hochschule Hannover /ID# 200632
Hanover, , Germany
General Hospital of Athens Gennimatas /ID# 210129
Athens, Attica, Greece
General Hospital of Athens Ippokratio /ID# 202181
Athens, Attica, Greece
424 General MILITARY Hospital /ID# 210973
Efkarpia (Thessalonikis), Thessaloniki, Greece
Debreceni Egyetem-Klinikai Kozpont /ID# 201526
Debrecen, Hajdú-Bihar, Hungary
Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz /ID# 204018
Budapest, , Hungary
Orszagos Reumatologiai es Fizioterapias Intezet /ID# 211454
Budapest, , Hungary
Del-Budai Centrumkorhaz Szent Imre Egyetemi Oktatokorhaz /ID# 201838
Budapest, , Hungary
Bnai Zion Medical Center /ID# 240733
Haifa, H_efa, Israel
The Lady Davis Carmel Medical Center /ID# 240731
Haifa, H_efa, Israel
The Chaim Sheba Medical Center /ID# 241041
Ramat Gan, Tel Aviv, Israel
Azienda Sanitaria dell'Alto Adige /ID# 200081
Bolzano, , Italy
Azienda Ospedaliero-Universitaria di Modena /ID# 200079
Modena, , Italy
Azienda Ospedaliera Universitaria Friuli Centrale/Presidio Ospedaliero Universit /ID# 200082
Udine, , Italy
Japan Organization of Occupational Health and Safety Chubu Rosai Hospital /ID# 202946
Nagoya, Aichi-ken, Japan
Kagawa University Hospital /ID# 200171
Kita-gun, Kagawa-ken, Japan
St. Marianna University Hospital /ID# 218692
Kawasaki-shi, Kanagawa, Japan
Duplicate_Japanese Red Cross Kumamoto Hospital /ID# 203507
Kumamoto, Kumamoto, Japan
Tohoku University Hospital /ID# 200172
Sendai, Miyagi, Japan
Okayama University Hospital /ID# 203156
Okayama, Okayama-ken, Japan
Tomishiro Central Hospital /ID# 203897
Tomigusuku-shi, Okinawa, Japan
Sakai City Medical Center /ID# 202643
Sakai-shi, Osaka, Japan
Duplicate_Jichi Medical University Hosp /ID# 200169
Shimotsuke-shi, Tochigi, Japan
St.Luke's International Hospital /ID# 200170
Chuo-ku, Tokyo, Japan
Radboud Universitair Medisch Centrum /ID# 212925
Nijmegen, Gelderland, Netherlands
Zuyderland Medisch Centrum /ID# 224551
Heerlen, Limburg, Netherlands
ZiekenhuisGroep Twente /ID# 200038
Almelo, Overijssel, Netherlands
Medisch Centrum Leeuwarden /ID# 201716
Leeuwarden, Provincie Friesland, Netherlands
Duplicate_Erasmus Medisch Centrum /ID# 201717
Rotterdam, South Holland, Netherlands
Universitair Medisch Centrum Groningen /ID# 201715
Groningen, , Netherlands
Optimal Clinical Trials Ltd /ID# 201946
Grafotn, Auckland, New Zealand
Aotearoa Clinical Trials /ID# 201942
Papatoetoe, Auckland, New Zealand
Timaru Medical Specialists Ltd /ID# 201943
Timaru, Canterbury, New Zealand
Waikato Hospital /ID# 201944
Hamilton, Waikato Region, New Zealand
CGM Research Trust /ID# 224061
Christchurch Central, , New Zealand
Porter Rheumatology Ltd /ID# 223830
Nelson, , New Zealand
Drammen Sykehus /ID# 201560
Drammen, Buskerud, Norway
Haukeland universitetssjukehus /ID# 201602
Bergen, Hordaland, Norway
Rikshospitalet OUS HF /ID# 202004
Oslo, , Norway
Unidade Local de Saude de Gaia/Espinho, EPE /ID# 208151
Vila Nova de Gaia, Porto District, Portugal
Unidade Local de Saúde do Alto Minho, EPE - Hospital Conde de Bertiandos /ID# 205186
Ponte de Lima, Viana do Castelo District, Portugal
Unidade Local de Saúde da Guarda, EPE /ID# 224878
Guarda, , Portugal
Unidade Local de Saude de Santa Maria, EPE /ID# 203530
Lisbon, , Portugal
Spitalul Clinic Judetean de Urgenta Cluj -Napoca /ID# 204887
Cluj-Napoca, Cluj, Romania
Cabinet Medical Dr. Avram S.R.L /ID# 224336
Timișoara, Timiș County, Romania
Spitalul Clinic Sf. Maria /ID# 203809
Bucharest, , Romania
Spitalul Clinic Colentina /ID# 204889
Bucharest, , Romania
Kemerovo State Medical University /ID# 203676
Kemerovo, Kemerovo Oblast, Russia
Moscow Regional Research and Clinical Institute n.a. Vladimirskiy (MONIKI) /ID# 221643
Moscow, Moscow Oblast, Russia
Practicheskaya Medicina Clinic /ID# 224612
Moscow, , Russia
First Moscow State Medical University n.a I.M. Sechenov /ID# 203673
Moscow, , Russia
Euromedservice /ID# 205345
Pushkin, , Russia
Clinical Rheumatologic Hospital No 25 /ID# 208950
Saint Petersburg, , Russia
Complejo Hospitalario Universitario A Coruña /ID# 224731
A Coruña, A Coruna, Spain
Hospital Universitario Marques de Valdecilla /ID# 201604
Santander, Cantabria, Spain
Hospital Meixoeiro (CHUVI) /ID# 212084
Vigo, Pontevedra, Spain
Hospital Universitario Canarias /ID# 224928
San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain
Hospital Universitario Basurto /ID# 224730
Bilbao, Vizcaya, Spain
Hospital Clinic de Barcelona /ID# 201878
Barcelona, , Spain
Hospital Universitario Virgen de las Nieves /ID# 224726
Granada, , Spain
Hospital General Universitario Gregorio Maranon /ID# 201326
Madrid, , Spain
Hospital Clinico San Carlos /ID# 204871
Madrid, , Spain
Hospital Universitario La Paz /ID# 241848
Madrid, , Spain
Skane University hospital /ID# 171407
Malmo, Skåne County, Sweden
Karolinska University Hospital Solna /ID# 204945
Solna, Stockholm County, Sweden
Uppsala University Hospital /ID# 171403
Uppsala, Uppsala County, Sweden
Sahlgrenska Universitetssjukhuset /ID# 171405
Gothenburg, Västra Götaland County, Sweden
Duplicate_Danderyds sjukhus /ID# 171404
Stockholm, , Sweden
Duplicate_Vastmanlands Sjukhus /ID# 171429
Västerås, , Sweden
Universitätsspital Basel /ID# 201767
Basel Town, Canton of Basel-City, Switzerland
Kantonsspital St. Gallen /ID# 201134
Sankt Gallen, Canton of St. Gallen, Switzerland
Inselspital, Universitaetsspital Bern /ID# 201364
Bern, , Switzerland
HFR Fribourg - Hôpital cantonal /ID# 201114
Fribourg, , Switzerland
Royal United Hospitals Bath /ID# 239850
Bath, Bath And North East Somerset, United Kingdom
Royal Devon & Exeter Hospital /ID# 202834
Exeter, Devon, United Kingdom
University Hospitals Dorset NHS Foundation Trust /ID# 202836
Poole, Dorset, United Kingdom
Barts Health NHS Trust /ID# 210511
London, Greater London, United Kingdom
UH Coventry & Warwickshire /ID# 202838
Coventry, Warwickshire, United Kingdom
Liverpool University University Hospitals NHS Foundation Trust /ID# 240391
Liverpool, , United Kingdom
Portsmouth Hospitals University NHS Trust /ID# 225002
Portsmouth, , United Kingdom
Southend Hospital /ID# 202839
Southend, , United Kingdom
Torbay and South Devon Nhs Foundation Trust /Id# 224689
Torquay, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Blockmans D, Penn SK, Setty AR, Schmidt WA, Rubbert-Roth A, Hauge EM, Keen HI, Ishii T, Khalidi N, Dejaco C, Cid MC, Hellmich B, Liu M, Zhao W, Lagunes I, Romero AB, Wung PK, Merkel PA; SELECT-GCA Study Group. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. N Engl J Med. 2025 May 29;392(20):2013-2024. doi: 10.1056/NEJMoa2413449. Epub 2025 Apr 2.
Loricera J, Tofade T, Prieto-Pena D, Romero-Yuste S, de Miguel E, Riveros-Frutos A, Ferraz-Amaro I, Labrador E, Maiz O, Becerra E, Narvaez J, Galindez-Agirregoikoa E, Gonzalez-Fernandez I, Urruticoechea-Arana A, Ramos-Calvo A, Lopez-Gutierrez F, Castaneda S, Unizony S, Blanco R. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature. Arthritis Res Ther. 2024 Jun 5;26(1):116. doi: 10.1186/s13075-024-03314-9.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Description Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-505476-29-00
Identifier Type: OTHER
Identifier Source: secondary_id
2017-003978-13
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
M16-852
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.